about
Inhibition of mitochondrial permeability transition pore restores the cardioprotection by postconditioning in diabetic heartsAffinity Purification of Tumor Necrosis Factor-α Expressed in Raji Cells by Produced scFv Antibody Coupled CNBr-Activated Sepharose.Development trends for generation of single-chain antibody fragments.Invert biopanning: A novel method for efficient and rapid isolation of scFvs by phage display technology.Isolation and characterization of a novel human scFv inhibiting EGFR vIII expressing cancers.Effect of Buspirone, Fluoxetine and 8-OH-DPAT on Striatal Expression of Bax, Caspase-3 and Bcl-2 Proteins in 6-Hydroxydopamine-Induced Hemi-Parkinsonian Rats.Major components of metabolic syndrome and nutritional intakes in different genotype of UCP2 -866G/A gene polymorphisms in patients with NAFLD.Patterns of Drug Resistance Among Tuberculosis Patients in West and Northwestern Iran.Rapid Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using Real-Time PCR.Antibody humanization methods - a review and update.Antibody humanization methods for development of therapeutic applications.Recent advances in head and neck squamous cell carcinoma--a review.Natural inhibitors of PI3K/AKT signaling in breast cancer: emphasis on newly-discovered molecular mechanisms of action.The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR).CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.Development and evaluation of a single domain antibody against human epidermal growth factor receptor (EGFR).Optimized condition for enhanced soluble-expression of recombinant mutant anabaena variabilis phenylalanine ammonia lyase.Development and Evaluation of a Cetuximab-based Humanized Single Chain Antibody Against EGFR-overexpressing Tumors.Design, expression and characterization of a single chain anti-CD20 antibody; a germline humanized antibody derived from Rituximab.Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.Targeted therapy of solid tumors by monoclonal antibody specific to epidermal growth factor receptor.humMR1, a highly specific humanized single chain antibody for targeting EGFRvIII.Comparative Evaluation of RUT, PCR and ELISA Tests for Detection of Infection with Cytotoxigenic H. pyloriThe effects of 5-fluorouracil alone and in combination with 13-cis retinoic acid and vitamin D3 on human oral squamous cell carcinoma lines.Epidemiology and patterns of drug resistance among tuberculosis patients in Northwestern Iran.Prevalence of Aminoglycoside Resistance Genes in Acinetobacter baumannii IsolatesPrevalence and risk factors of drug-resistant tuberculosis in border provinces of Iran.Effects of Nigella sativa oil with a low-calorie diet on cardiometabolic risk factors in obese women: a randomized controlled clinical trial.Chaperone-Assisted Soluble Expression of a Humanized Anti-EGFR ScFv Antibody in E. Coli.Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats.Molecular Cloning and Characterization of P4 Nuclease from Leishmania infantum.Antimicrobial Resistance Patterns and Prevalence of blaPER-1 and blaVEB-1 Genes Among ESBL-producing Pseudomonas aeruginosa Isolates in West of IranDose-Dependent Effect of Flouxetine on 6-OHDA-Induced Catalepsy in Male Rats: A Possible Involvement of 5-HT1A Receptors.The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats.Minocycline prevents morphine-induced apoptosis in rat cerebral cortex and lumbar spinal cord: a possible mechanism for attenuating morphine tolerance.Engineering and kinetic stabilization of the therapeutic enzyme Anabeana variabilis phenylalanine ammonia lyase.Protein L: a robust enzyme-conjugated molecule for detection of humanized single chain antibodies.Causative agents and antimicrobial susceptibilities of urinary tract infections in the northwest of Iran.Molecular characterization of a novel amastigote stage specific Class I nuclease from Leishmania major.
P50
Q34586543-C43D3D63-7500-47F8-9609-ABEDF699C17AQ35061620-3F0C7065-0A51-4103-AC27-4463EA31EC3EQ35216785-37D08045-30D3-49D5-9093-FA0F84E7A4A4Q36103286-471CEC48-43DA-4DC3-8035-B76B23391ADDQ36226672-99A390D1-438E-4BAE-8EE6-1BCCF81DB726Q36509473-0496B840-2B2C-4540-ACE9-D8E2ACA928C0Q37006682-498946D3-B725-4429-B8C3-E74002779597Q37192872-0034DE6D-33F7-4FF9-BB5F-D2C1786549FFQ37471030-3CB35B7F-D9AD-464C-8C18-2AECF5D506B8Q38191015-E9117665-8F4A-446C-A2C3-C07B1588F322Q38205579-96EFC6C3-6FFD-4AF1-A4A1-ACC6BD6E22B7Q38218802-3AFA4AD1-A09C-4C40-963E-6AA6796A88BCQ38297806-1E2631E3-66B2-4B21-B76D-628B1D72DCA1Q38577849-10B037C1-11EC-44E0-82EE-4E0FFDB0ED43Q38764620-41342931-5A53-49EA-8761-57CEAD18C29EQ38807514-94CB0F17-CE30-40A1-B00A-DC0457DC0B38Q38810011-5D336C19-4171-42F2-9D0F-2721277FA027Q38845073-82ED2199-9A62-4D58-A0E5-B9A6C1BB2948Q38946247-E4FC6111-7031-4693-A438-B4D4E1940DD4Q38969046-CFC6F8F4-55D1-46D1-B20B-A021D06C2036Q38999243-1D185A1F-D13C-4197-BCEF-83F9C2D7F84AQ39039316-C0E29001-BE53-4D6B-A7D9-5B6439A88EB8Q39039752-D2C4D3DB-A15D-4BF5-9214-40708B3AE5B1Q39099897-60409AF1-9047-4D13-81FF-829E2388D361Q39291968-F978D7B0-0E0B-4CAC-9CC2-6744C15DBE0CQ40397009-C6BC0C5E-BA71-4AD9-92C4-9518F13C4A12Q41515547-1D787BD2-C6EE-4542-97E7-7E0F01C7C1CCQ41587090-139BA441-AC32-4E2F-B08F-A68CC97E18E8Q41704281-17B90AA2-E02B-460C-8139-166487079BB3Q42012779-18357FEF-E13C-4990-89DB-F98557367872Q42458161-0F8144E5-424D-4F0E-9576-B6FDDDA665D6Q42791738-9877EA69-AA04-4057-B852-D15E5A862482Q42819064-33EA3BDE-067A-4155-B8B5-B9E8E328F7A8Q42856693-DDFB464D-F36A-484C-A414-89FC3D67C861Q42856741-22F19FAA-E1D2-4EF2-BF1A-A02C52CFDB79Q42936784-364BE5B7-81B9-4EC8-B5DB-E08BAFFD85F8Q45010181-FEBB7214-28B7-4111-9ED3-57A5D8B16957Q45799710-CD3A432E-9BB7-421C-AAD0-A918145B8E40Q46429406-B22B38FA-3C36-4515-8C47-0BFA8D569CB8Q47291116-66FC0997-6C64-45C8-B2D9-353B9048104F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Safar Farajnia
@ast
Safar Farajnia
@en
Safar Farajnia
@es
Safar Farajnia
@nl
Safar Farajnia
@sl
type
label
Safar Farajnia
@ast
Safar Farajnia
@en
Safar Farajnia
@es
Safar Farajnia
@nl
Safar Farajnia
@sl
prefLabel
Safar Farajnia
@ast
Safar Farajnia
@en
Safar Farajnia
@es
Safar Farajnia
@nl
Safar Farajnia
@sl
P106
P1153
35268422200
P31
P496
0000-0002-6087-9147